Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Med1 May Explain the Interaction Between Receptor Tyrosine Kinases and Erα66 in the Complicated Network of Tamoxifen Resistance Publisher Pubmed



Mansouri S1 ; Naghavialhosseini F1 ; Farahmand L1 ; Majidzadeha K2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  2. 2. Cancer Genetics Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran

Source: European Journal of Pharmacology Published:2017


Abstract

According to the American Society of Clinical Oncology or ASCO's clinical practice guidelines, administration of Tamoxifen for hormone receptor positive patients improved outcomes. However, many studies have been conducted in this issue, with the rise of Tamoxifen resistance in recent decades. There are many alternative growth cascades that are activated in Tamoxifen resistant cells. The most common and well characterized components of such a resistant network are receptor tyrosine kinases, or RTKs, which can influence many other cellular processes. The interactions between estrogen dependent and independent pathways further complicate the networking. MED1, as a member of a mediator complex, which is activated by RTK growth pathways, plays role in co-activating ERα66 to transcribe genes and enhance cellular proliferation. Herein, we will discuss MED1, a novel biomarker which can explain how RTKs interact with ERα66 which results in Tamoxifen resistance. © 2017 Elsevier B.V.
Related Docs
1. Challenges of Endocrine Therapy in Breast Cancer, Cancer Genetics and Psychotherapy (2017)
2. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance Is Required, Current Cancer Drug Targets (2018)
3. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May Be Induced by Interactions Between Receptor Tyrosine Kinases and Erα-66, Recent Patents on Anti-Cancer Drug Discovery (2018)
4. Er-Α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance, Clinical Breast Cancer (2017)
5. Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients, Tissue and Cell (2018)
6. Evaluating Human Epidermal Growth Factor Receptor 2 Roles in the Efficacy of Tamoxifen Treatment in Breast Cancer, a Systematic Review, Pharmacological Reports (2021)